Outcomes and Cost of Coronary Artery Bypass Graft Surgery in the United States and Canada

Eisenberg, Mark J.; Filion, Kristian B.; Azoulay, Arik; Brox, Anya C.; Haider, Seema; Pilote, Louise

doi:10.1016/j.accreview.2005.09.084

Cited by 15 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronary artery bypass grafting (CABG) is an established revascularization procedure for the treatment of advanced atherothrombotic coronary artery disease. 1 The National Center for Health Statistics estimated that 427,000 procedures were performed on 249,000 patients in the United States in 2004. 2 Antiplatelet drugs, particularly aspirin, are considered a mainstay for both primary and secondary prevention in atherothrombotic coronary artery disease.…”

mentioning

confidence: 99%

Clopidogrel‐Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting

Pickard¹,

Becker²,

Schumock³

et al. 2008

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Clopidogrel‐Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting

Pickard¹,

Becker²,

Schumock³

et al. 2008

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Average LOS has been observed to be higher in Canadian hospitals as compared to their US counterparts across different admission diagnoses, such as coronary artery bypass graft surgery and heart failure. 9,10 We hypothesize that these differences are party due to systems-level differences, including posthospital care. Specifically, the Canadian system does not utilize posthospital acute care, such as skilled nursing facilities, which may in part account for these differences.…”

Section: Methodsmentioning

confidence: 99%

Impact of an innovative inpatient patient navigator program on length of stay and 30‐day readmission

Kwan

Morgan

Stewart

et al. 2015

Journal of Hospital Medicine

View full text Add to dashboard Cite

BACKGROUND The current climate of increasing patient complexity coupled with rising costs have prompted the need for adaptive innovation. There are limited data describing inpatient interventions targeting improvements in both communication and transitional care. OBJECTIVE Evaluate the patient navigator (PN) program, an innovative inpatient intervention intended to enhance navigation through the complexity of hospital admissions for patients and providers. INTERVENTION PNs were dedicated patient‐care facilitators without clinical responsibilities integrated as full members of the inpatient care team responsible for enhancing communication between and among patients and providers. DESIGN Observational retrospective cohort study. PATIENTS All patients admitted to the general medical service between July 2010 and March 2014. SETTING Academic medical center. MEASUREMENTS Primary outcomes were hospital length of stay (LOS) and 30‐day readmission rate matched by case mix group, age category, and resource intensity weight. RESULTS Our matched cohort included 5628 admissions (4592 patients) exposed and 2213 admissions (1920 patients) not exposed to PNs. Admissions with PNs were 1.3 days (21%) shorter than admission without PNs (6.2 vs 7.5 days, P < 0.001). Thirty‐day readmission rate was not different between the 2 groups (13.1 vs 13.8%, P = 0.48). CONCLUSION Implementation of this intervention was associated with a reduction in LOS without an increase in 30‐day readmission. Journal of Hospital Medicine 2015;10:799–803. © 2015 Society of Hospital Medicine

show abstract

“…All input parameters in the model are listed in Table 1. For CVD patients 25% (almond) -Chen et al [11] 35% (non-almond) -Chen et al [11] Developing MI 0.38% -Pikula et al [12] 3.75%* -Pikula et al [12] 1.04% ± 0.91% Beta Multiple sources [12,13] Death due to MI 14% -Benjamin et al [14] Taking CABG 0.11% -Epstein et al [15] Death due to CABG 1.85% -Eisenberg et al [16] Taking PTCA 0.37% -Epstein et al [15] Death due to PTCA 1.82% -Benjamin et al [14] Developing stroke 0.25% -Pikula et al [12] 2.46%* -Pikula et al [12] 0.099% ± 0. Cost per quality-adjusted life year threshold…”

Section: Quality-adjusted Life Yearmentioning

confidence: 99%

Daily almond consumption in cardiovascular disease prevention via LDL-C change in the U.S. population: a cost-effectiveness analysis

et al. 2020

View full text Add to dashboard Cite

Background: Heart disease is the leading cause of death in the United States. The U.S. Food and Drug Administration approved the health claim that 1.5 oz (42.5 g) of nut intake may reduce the risk of cardiovascular disease. Previous studies have focused on the cost-effectiveness of other foods or dietary factors on primary cardiovascular disease prevention, yet not in almond consumption. This study aimed to examine the costeffectiveness of almond consumption in cardiovascular disease primary prevention. Perspective & Setting: This study assessed the cost-effectiveness of consuming 42.5 g of almond from the U.S. healthcare sector perspective. Methods: A decision model was developed for 42.5 g of almond per day versus no almond consumption and cardiovascular disease in the U.S. population. Parameters in the model were derived from the literature, which included the probabilities of increasing low-density lipoprotein cholesterol, developing acute myocardial infarction and stroke, treating acute myocardial infarction, dying from the disease and surgery, as well as the costs of the disease and procedures in the U.S. population, and the quality-adjusted life years. The cost of almonds was based on the current price in the U.S. market. Sensitivity analyses were conducted for different levels of willingness-to-pay, the probabilistic sensitivity analysis, ten-year risk prevention, different costs of procedures and almond prices, and patients with or without cardiovascular disease. Results: The almond strategy had $363 lower cost and 0.02 higher quality-adjusted life years gain compared to the non-almond strategy in the base-case model. The annual net monetary benefit of almond consumption was $1421 higher per person than no almond consumption, when the willingness to pay threshold was set at $50,000 for annual health care expenditure. Almond was more cost-effective than non-almond in cardiovascular disease prevention in all the sensitivity analyses. Conclusion: Consuming 42.5 g of almonds per day is a cost-effective approach to prevent cardiovascular disease in the short term and potentially in the long term.

show abstract

Outcomes and Cost of Coronary Artery Bypass Graft Surgery in the United States and Canada

Cited by 15 publications

References 16 publications

Clopidogrel‐Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting

Clopidogrel‐Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting

Impact of an innovative inpatient patient navigator program on length of stay and 30‐day readmission

Daily almond consumption in cardiovascular disease prevention via LDL-C change in the U.S. population: a cost-effectiveness analysis

Contact Info

Product

Resources

About